Author Correction: Preclinical comparison of prolgolimab, pembrolizumab and nivolumab

Author Correction: Preclinical comparison of prolgolimab, pembrolizumab and nivolumab

Saved in:

Bibliographic Details
Main Authors:	Aleksandr Gordeev, Andrei Vaal, Maria Puchkova, Iana Smirnova, Aleksandr Doronin, Anna Znobishcheva, Daria Zhmudanova, Aleksei Aleksandrov, Mikhail Sukchev, Evgeny Imyanitov, Valery Solovyev, Pavel Iakovlev
Format:	Article
Language:	English
Published:	Nature Portfolio 2024-11-01
Series:	Scientific Reports
Online Access:	https://doi.org/10.1038/s41598-024-77480-w
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Preclinical comparison of prolgolimab, pembrolizumab and nivolumab
by: Aleksandr Gordeev, et al.
Published: (2024-10-01)

Effectiveness and safety of atezolizumab, nivolumab and pembrolizumab in metastatic non-small cell lung cancer
by: Amparo Burgos-San José, et al.
Published: (2021-05-01)

Effectiveness and safety of pembrolizumab, nivolumab, and atezolizumab as adjuvant therapy for high-risk muscle-invasive urothelial carcinoma: an indirect comparison
by: Wei Chen, et al.
Published: (2025-01-01)

Durable Clinical Benefit after Dual Checkpoint Inhibition and Single-agent Nivolumab Following Pembrolizumab Failure in Mismatch Repair-deficient Colon Cancer
by: Yat-Fung Chow, et al.
Published: (2023-10-01)

The experimental study of energy dissipation during fatigue crack propagation under biaxial loading
by: Oleg Plekhov, et al.
Published: (2019-04-01)

The experimental study of heat dissipation during fatigue crack propagation under biaxial loading
by: Aleksei Vshivkov, et al.
Published: (2019-02-01)

Long-Term Temporal Trends of Real-World Healthcare Costs Associated with Nivolumab Plus Ipilimumab and Pembrolizumab Plus Axitinib as First-Line Treatment for Advanced or Metastatic Renal Cell Carcinoma
by: Ella Xiaoyan Du, et al.
Published: (2024-08-01)

Analysis of reservoir rock permeability changes due to solid precipitation during waterflooding using artificial neural network
by: Azizollah Khormali, et al.
Published: (2025-01-01)

Couple effects of temperature and fatigue, creep-fatigue interaction and thermo-mechanical loading conditions on crack growth rate of nickel-based alloy
by: Valery Shlyannikov, et al.
Published: (2022-07-01)

Features of Adjusting the Frozen Soil Properties Using Borehole Temperature Measurements
by: Mikhail Semin, et al.
Published: (2021-01-01)

Evaluation of Nivolumab for Ototoxic Effects: An Animal Study in Rats
by: İsmail Güler, et al.
Published: (2020-08-01)

Fulminant Diabetes in a Patient with Advanced Melanoma on Nivolumab
by: Nora Chokr, et al.
Published: (2018-01-01)

Refractory Acute Interstitial Nephritis in the Setting of Nivolumab Therapy
by: Antonio Faieta, et al.
Published: (2021-01-01)

Retinal Toxicity after Initial Administration of Nivolumab and Ipilimumab
by: Adnan Kilani, et al.
Published: (2023-01-01)

Nivolumab and dinutuximab beta in two patients with refractory neuroblastoma
by: Holger Lode, et al.
Published: (2020-05-01)

Nivolumab Efficacy and Safety in Cancer Patients with Renal Dysfunction
by: Ezgi Degerli, et al.
Published: (2024-09-01)

Acquired lipodystrophy following use of pembrolizumab
by: Maya Weitzen, et al.
Published: (2024-12-01)

Hypertrophic Lichen Planus associated with Pembrolizumab
by: M. Sato-Sano, et al.
Published: (2024-01-01)

Pembrolizumab‐induced acquired perforating dermatosis
by: Yaron Gu, et al.
Published: (2024-12-01)

A Case of Nivolumab-Induced Severe Mononeuropathy Multiplex and Rhabdomyolysis
by: Katsuya Sakai, et al.
Published: (2017-01-01)

Hidradenitis suppurativa induced by ipilimumab and nivolumab: A rare association
by: Alexander D. Woods, MD, et al.
Published: (2025-03-01)

Ipilimumab and nivolumab in uveal melanoma: report on toxicity and treatment intensity
by: A. Ciernik, et al.
Published: (2024-01-01)

Unusual gingival presentation following treatment with pembrolizumab
by: Annu Singh, et al.
Published: (2024-03-01)

The search for an optimal tissue‐engineered urethra model for clinical application based on preclinical trials in male animals: A systematic review and meta‐analysis
by: Natalia Chepelova, et al.
Published: (2024-11-01)

Toxic epidermal necrolysis induced by nivolumab therapy for unresectable intraperitoneal cancer
by: Hiroyoshi Nozaki, et al.
Published: (2025-01-01)

Duration of nivolumab for pretreated, advanced non–small‐cell lung cancer
by: Margaux Geier, et al.
Published: (2020-10-01)

Nivolumab and Ipilimumab Combination Immunotherapy for Patients with Metastatic Collecting Duct Carcinoma
by: Tetsuya Danno, et al.
Published: (2021-01-01)

Nivolumab-Induced Encephalitis in Hereditary Leiomyomatosis and Renal Cell Cancer Syndrome
by: Benjamin Chaucer, et al.
Published: (2018-01-01)

Re-exposition to ipilimumab plus nivolumab in metastatic Merkel cell carcinoma
by: Valerie Glutsch, et al.
Published: (2024-12-01)

Disseminated nummular eczema following nivolumab treatment: Successful management with dupilumab
by: Betzabé Quiles Martínez, et al.
Published: (2024-12-01)

Heat dissipation and fatigue crack kinetic features of titanium alloy Grade 2 after laser shock peening
by: Anastasia Iziumova, et al.
Published: (2022-09-01)

Heat dissipation and fatigue crack kinetic features of titanium alloy Grade 2 after laser shock peening
by: Anastasia Iziumova, et al.
Published: (2022-09-01)

RETRACTED: Use of industrial waste in the production of non-autoclaved foam concrete
by: Vishtorsky Evgeny, et al.
Published: (2024-01-01)

Identifying factors for pembrolizumab eligibility in head and neck cancer
by: Satoru Miyamaru, et al.
Published: (2025-02-01)

An Episode of Pseudothrombocytopenia during Pembrolizumab Therapy in NSCLC Patient
by: Kinga Krukowska, et al.
Published: (2020-01-01)

Low‐dose nivolumab for extranodal natural killer/T‐cell lymphoma, nasal type
by: Satish Maharaj, et al.
Published: (2024-12-01)

Desensitization protocol to nivolumab without corticosteroid use in a kidney cancer patient
by: Sebastián Ramírez-Cruz, et al.
Published: (2020-07-01)

Postoperative pyoderma gangrenosum in a patient undergoing long-term nivolumab therapy
by: Miki Sato, et al.
Published: (2024-11-01)

Treatment-free survival outcomes from the phase II study of nivolumab and salvage nivolumab/ipilimumab in advanced clear cell renal cell carcinoma (HCRN GU16-260-Cohort A)
by: Michael Hurwitz, et al.
Published: (2024-04-01)

A phase 2 study of frontline pembrolizumab in follicular lymphoma
by: Carrie Ho, et al.
Published: (2024-12-01)